{"id":"W2618414114","doi":"10.1093/cid/cix289","title":"Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study","year":2017,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"Hepatitis C virus research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vancouver General Hospital; Ottawa Hospital; University of Calgary; Centre Hospitalier de l’Université de Montréal; William Osler Health System; Université Laval; University of Alberta; Toronto Liver Centre; London Health Sciences Centre; University of Toronto","funders":"Merck Canada; Novo Nordisk; Eisai; Bristol-Myers Squibb Canada; Gilead Sciences; Intercept Pharmaceuticals; AbbVie Canada; Vertex Pharmaceuticals; Genentech; Celgene; Pfizer","keywords":"Medicine; Sofosbuvir; Ledipasvir; Ribavirin; Internal medicine; Cirrhosis; Gastroenterology; Tolerability; Hepatitis C; Discontinuation; Adverse effect; Hepatitis C virus; Clinical endpoint; Clinical trial; Virology; Virus","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002367692,0.001032364,0.002817061,0.0003549471,0.0005417441,0.0008617263,0.0007022122,0.001286259,0.002875997],"category_scores_gemma":[0.001892487,0.0005155848,0.0014575,0.0004868618,0.001057272,0.0009660762,0.0003143969,0.002094215,0.0004905629],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00103302,"about_ca_system_score_gemma":0.001808397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001822295,"about_ca_topic_score_gemma":0.003047042,"domain_scores_codex":[0.998859,0.0006973448,0.00008103321,0.0001271774,0.0001136767,0.0001216603],"domain_scores_gemma":[0.9982919,0.0005431849,0.000298929,0.0001482321,0.0001426636,0.0005750681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8503335,0.06683128,0.007107017,0.001293191,0.001377526,0.0002925631,0.0003510102,0.0009027962,0.00948212,0.0001147858,0.001023497,0.06089069],"study_design_scores_gemma":[0.6545007,0.3316776,0.01067252,0.00005999016,0.0003569298,0.0001302135,0.00006094859,0.0008585138,0.0005502744,0.00006925586,0.001034146,0.00002890664],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948798,0.001798334,0.0003662489,0.0002027478,0.0001253719,0.001422999,0.00047189,0.00003792258,0.0006946221],"genre_scores_gemma":[0.9932936,0.001639163,0.00106527,0.0004884981,0.000299979,0.0018551,0.0006985214,0.00001035042,0.0006495077],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002875997,"threshold_uncertainty_score":0.01252168,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1450004601176128,"score_gpt":0.4708356461323177,"score_spread":0.325835186014705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}